目的：探讨玻璃体腔注射改良低剂量曲安奈德(TA)治疗白内障术后黄斑囊样水肿(PCME)的疗效。

方法：回顾性分析。选取2015-01/2018-12于我院就诊的典型PCME 患者12例12眼行玻璃体腔注射改良低剂量TA。通过0.22μm的滤膜将TA 混悬液置换成眼内灌注液，取置换后的TA溶液2mg/0.05mL注射。观察注药后2wk，1、3、6mo的最佳矫正视力、黄斑中央厚度、眼压、局部和全身并发症。

结果：与注射前比较，所有患者注药后视力均显著提高； 黄斑中央厚度显著减低(P<0.05)， 而眼压无明显升高(P>0.05)，所有患者均未观察到眼部及全身并发症。

结论：玻璃体腔注射改良低剂量TA治疗PCME安全、有效，克服了以往导致眼压升高的副作用，价格低廉，能够使患者受益。但尚需大宗病例的临床随机对照研究和长期疗效的随访观察。

METHODS: Retrospective study. Totally 12 eyes of 12 patients with PCME in our hospital were received intravitreal injection with modified low doses of TA from 2015-01 to 2018-12. The TA suspension was firstly resuspended by intraocular irrigating solution through 0.22um pore filter, then the new TA suspension(2mg/0.05mL)was injected intravitreally. The best-corrected visual acuity(BCVA), central macular thickness(CMT), intraocular pressure(IOP), and other side effects were recorded at 2wk, 1mo, 3mo and 6mo after injection, then compared the data with pre-injection(baseline)information.

RESULTS: After intravitreal injection of modified low dose TA, all patients got improved BCVA and alleviated CMT, as compare to the baseline data, and the difference was statistically significant(P<0.05), but the difference of IOP was not significant(P>0.05). All patients had no recorded ocular or systemic complication.

CONCLUSION: Intravitreal injection of modified low-dose TA is effective and safe for PCME, without significant increase in IOP. It's an affordable substitution to anti-vascular endothelial growth factor(anti-VEGF)agents. This still needs to be confirmed by the long-term follow-up study with large samples.